Kyung Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 15, 2021 at 02:05 am EST
Share
Kyung Dong Pharmaceutical Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was KRW 49,358.13 million compared to KRW 45,796.2 million a year ago. Net income was KRW 5,101.24 million compared to KRW 3,193.19 million a year ago. Basic earnings per share from continuing operations was KRW 185 compared to KRW 136 a year ago. Diluted earnings per share from continuing operations was KRW 185 compared to KRW 154 a year ago. Basic earnings per share was KRW 185 compared to KRW 136 a year ago.
For the nine months, sales was KRW 130,716.94 million compared to KRW 128,650.58 million a year ago. Net income was KRW 10,635.15 million compared to KRW 9,517.56 million a year ago. Basic earnings per share from continuing operations was KRW 385 compared to KRW 404 a year ago. Diluted earnings per share from continuing operations was KRW 385 compared to KRW 394 a year ago. Basic earnings per share was KRW 385 compared to KRW 404 a year ago.
KYUNG DONG PHARMACEUTICAL CO.,LTD. is a Korea-based company engaged in the manufacture and marketing of pharmaceutical products. The Companyâs products include liver therapies, gastrointestinal drugs, antimigraine drugs, antiviral, anti-obesity medications, antibacterial drugs, antidiabetic drugs, antifungal, allergy medications, antispasmodics, antihistamines, vitamins, as well as drugs for osteoporosis, cardiovascular, muscle relaxant, neuropathic and other diseases. It also provides various over-the-counter (OTC) drugs, such as anti-inflammatory medicines, antiviral drugs, antihistamine drugs, gastrointestinal drugs and others. In addition, the Company engages in the leasing of real estate, and distribution of snowboards and health functional food.
KYUNG DONG PHARMACEUTICAL CO., LTD. 